Virpax Pharmaceuticals, Inc. (VRPX) News
Filter VRPX News Items
VRPX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest VRPX News From Around the Web
Below are the latest news stories about VIRPAX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VRPX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to dive into the biggest pre-market stock movers for Friday morning as we check out the winners and losers today! |
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q FilingBERWYN, Pa., November 17, 2023--Virpax Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing |
Virpax Pharmaceuticals Announces Leadership TransitionBERWYN, Pa., November 17, 2023--Virpax Announces Leadership Transition |
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent DevelopmentsBERWYN, Pa., November 15, 2023--Virpax Reports 2023 Third Quarter Results and Recent Developments |
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA ReviewBERWYN, Pa., October 31, 2023--Virpax Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review |
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical ResearchBERWYN, Pa., October 12, 2023--Virpax Announces Extension of CRADA with the U.S. Army Institute of Surgical Research |
Gerald W. Bruce Appointed President and CEO of Novvae™ PharmaceuticalsBERWYN, Pa., October 02, 2023--Gerald W. Bruce Appointed President and CEO of Novvae™ |
Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation StudiesBERWYN, Pa., September 27, 2023--Virpax Announces Results of Probudur™ Dose Escalation Studies |
Virpax Pharmaceuticals to Present at the LD Micro Main Event XVIBERWYN, Pa., September 26, 2023--Virpax to Present at the LD Micro Main Event XVI |
Lab Notes: Main Line firm spins off company that will focus on OTC product pipelineThis week's roundup of recent Philadelphia-area life sciences news includes Galera pushing forward with radiation therapy side effect therapy despite FDA setback. |